No

Anticholinergic Agent

Adjunctive therapy in the treatment of peptic ulcer

C

Anticholinergic drugs decrease both esophageal and gastric motility and relax the lower esophageal sphincter and are contraindicated in the presence of reflux esophagitis; glaucoma; obstructed uropathy; obstructed disease of the GI tract (pyloroduodenal stenosis); paralytic ileus; intestinal atony of elderly or debilitated individuals; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon; complicated ulcerative colitis; myasthenia gravis; hypersensitivity to methscopolamine or related drugs

>10%:

Dermatologic: Dry skin

Gastrointestinal: Constipation, xerostomia, dry

Respiratory: Dry nose

Miscellaneous: Decreased diaphoresis

1% to 10%: Gastrointestinal: Dysphagia

No data reported

Methscopolamine is a peripheral anticholinergic agent that does not cross the blood-brain barrier and provides a peripheral blockade of muscarinic receptors. This agent reduces the volume and the total acid content of gastric secretions, inhibits salivation, and reduces gastrointestinal motility.

Adults: Oral: 2.5 mg 30 minutes before meals or food and 2.5-5 mg at bedtime

Should be administered 30 minutes before meals or food

May rarely cause drowsiness, confusion, amnesia, or nervousness

Concurrent use with psychotropics may produce additive sedation and dry mouth

No information available to require special precautions

>10% of patients experience dry mouth; anticholinergic side effects can cause a reduction of saliva production or secretion contributes to discomfort and dental disease (ie, caries, oral candidiasis and periodontal disease)

Tablet, as bromide: 2.5 mg